secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001655759-25-000095
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas/Pfizer vepdegestrant VERITAC-2: PFS benefit in ESR1m patients; NDA in H2 2025
--------------------------------------------------------------------------------

- In ESR1m patients, vepdegestrant reduced progression/death risk by 43% (HR=0.57); median PFS 5.0 vs 2.1 months (p<0.001).
- ITT population median PFS 3.7 vs 3.6 months (HR=0.83, p=0.07), not statistically significant.
- Secondary endpoints in ESR1m: ORR 18.6% vs 4.0% (OR 5.45), CBR 42.1% vs 20.2% (OR 2.88).
- Safety profile generally well tolerated; GI events low (nausea 13.5%); discontinuation 2.9% vs 0.7%.
- Companies plan to submit NDA to FDA in H2 2025; OS data immature at analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000095/0001655759-25-000095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000095/arvn-20250531.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer